Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danshen (salvia) tablets for post-PCI angina pectoris
ChiCTR2100047615Phase 4Recruiting
- Sponsor
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in angina pectoris and coronary arteriosclerosis comparing Danshen tablets with Control: placebo (2 arms). Primary endpoint: Angina pectoris scale. Started Jan 2021; status: recruiting.
02
Drugs
salvia miltiorrhiza
03
Conditions
angina pectoriscoronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2100047615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047615.